- Min.Order :100 Gram
- Purity: 99%
- Payment Terms : L/C,D/A,D/P,T/T,Other
Keywords
Erlotinib hydrochloride 183319-69-9 supplier 183319-69-9 price
Quick Details
- Appearance:Off-white Solid
- Application:pharmaceutical uses
- PackAge:Fluoride barrel
- ProductionCapacity:100|Kilogram|Week
- Storage:Protected from light, stored hermetically and in a dry place
- Transportation:By air or courier or sea
Superiority:
HENAN SUNLAKE ENTERPRISE CORPORATION
Our company advantages:
1、The highest quality with the competitive price.
2、Professional human services.
3、The fastest and safest delivery service.
4、The faster and safest delivery service.
5、The high purity products.
6、We have a sufficient supply of stock.
7、A variety of payments, such as L/C, TT, , MoneyGram or other payments.
Company Information
Henan Sunlake Enterprise Corporation is located in Henan Province , The central plain of China , Which enjoys favorable geogeaphical position and convenient transportion. The com[any was established in june. 1998, until now having more than 18 years experience in manufacturing & exporting chemical raw material .
Sunlake is a professional manufacturer engaged in producing and selling chemicals,including Organic & inorganic chemicals , pigments & Dyestuffs , Water treatment chemicals , Food & FEED additives and others. These products have been being well exported to europe, southeast Asia, the Middle East ,Africa, South America and some other countries and areas.
We sincerely welcome foreign friends to visit our plant for cooperation. With the idea of "quality first,credit priority, Excellent service", We are highly acknowledged by customers for good quality and competitive price. More importantly , the company has a strong R & D team, who are professional engineers and scholars with Ph. D. .So we are confident to serve you better with our high - quality products and professional team. We are taking great efforts to provide our customers with demanded goods and professional services, and continuously improve our core ability of competition and get the momentum for sustainable development, and finally make us being a reliable and professional supplier in international market.
We welcome any serious inquiries from all customers of the world, and sincerely hope to cooperate with you for a brilliant future!
Details:
Erlotinib hydrochloride Basic information
| Antineoplastic drug Erlotinib Application |
| Product Name: | Erlotinib hydrochloride |
| Synonyms: | ERLOTINIB HCL;ERLOTINIB HCL SALT;ERLOTINIB HCL SALT :TARCEVA;Erlotinib, Hydrochloride Salt;N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine, Hydrochloride Salt, OSI 774, Tarceva; N-(3-Ethynylphenyl)-6,7-bis-(2-methoxyethoxy)-quinazolin-4-amine;[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4yl]-(3-ethynyl-phenyl)-amine;Tarceva Hydrochloride See E625000 |
| CAS: | 183319-69-9 |
| MF: | C22H24ClN3O4 |
| MW: | 429.9 |
| EINECS: | |
| Product Categories: | API;Molecular Targeted Antineoplastic;Heterocyclic Compounds;anti-neoplastic;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Tarceva;Antineoplastic;Anti-cancer&immunity;Inhibitors |
| Mol File: | 183319-69-9.mol |
|
|
|
| Erlotinib hydrochloride Chemical Properties |
| mp | 223-225°C |
| storage temp. | -20°C Freezer |
| CAS DataBase Reference | 183319-69-9(CAS DataBase Reference) |
| Safety Information |
| Erlotinib hydrochloride Usage And Synthesis |
| Antineoplastic drug | Erlotinib hydrochloride is a kind of small molecule epidermal growth factor receptor tyrosine kinase reversible inhibitors. It is mainly used for the second-line or third-line treatment of the locally advanced or metastatic non-small cell lung cancer and for the treatment of pancreatic cancer. |
| Erlotinib |
Erlotinib hydrochloride is hydrochloride of molecular targeted drug erlotinib. The US Food and Drug Administration (FDA) has approved erlotinib (Tarceva) in combination with gemcitabine for the first-line treatment of locally advanced and metastatic pancreatic cancer. Small molecule compound erlotinib is a kind of receptor tyrosine kinase inhibitors. It can inhibit the phosphorylation reaction through competitively combined with the catalytic site of receptor tyrosine kinase tyrosine with the ATP, thus blocking the under proliferative signal transduction, and inhibiting the activity of tumor cell ligand-dependent HER-1/EGFR in order to inhibit tumor cell proliferation. Erlotinib is another tyrosine kinase inhibitor for treatment of NSCLC. The results ofⅠclinical trials showed that its main toxicity and side effect were dose-dependent skin rashes and diarrhea, other rare side effects were headache, nausea, vomiting and the like. Erlotinib is used as the second-line anticancer drugs in the Ⅱ clinical trial. Its effects are same as second-line chemotherapy drugs docetaxel. The Ⅲ clinical randomized controlled trials (BR21) [22] mainly aimed at NSCLC patients after the failure of first-line or second-line chemotherapy (locally advanced and having distant metastasis). The study group used erlotinib 150mg a day for a total of 488 cases. The control group used placebo for a total of 243 cases. The results were: the median overall survival: 6.7 months for the treatment group, 4.7 months for the control group (P<0.001, mortality ratio HR=0.73); survival rate for one year: 31.2% of the treatment group and 21.5% of control group; median progress time: 9.9 weeks for treatment group and 7.9 weeks for control group. Meanwhile the improvement of the patient's symptoms in the erlotinib group is more obvious. A number of Ⅲ clinical researches were conducted based on the results of BR21. TRIBUTE clinical trials used erlotinib in combination with chemotherapy in an attempt to compare that whether the efficacy of it combined with chemotherapy alone was better than chemotherapy or not. The treatment group used chemotherapy (carboplatin plus paclitaxel) and erlotinib, while control group used the same chemotherapy alone. There are a total of 1059 cases of patients with advanced NSCLC joined the observation. Results showed that the effective rate of the study group is 21.5%, and the effective rate of the control group is 19.3%. Median survival: 10.8 months for the study group, and 10.6 months for the control group; time to tumor progression (TTP): 5.1 months for the study group, 5.0 months for the study group. Another TALENT study is that whether the combination of erlotinib with chemotherapy (gemcitabine+cisplatin) is able to improve the efficacy of chemotherapyor not for a total of 1172 cases of NSCLC patients. The results also did not show that erlotinib could significantly improve the efficacy of chemotherapy. The above information is edited by the Chemicalbook of Ge Qian. |
| Application |
1. Erlotinib hydrochloride is a kind of small molecule epidermal growth factor receptor tyrosine kinase reversible inhibitor. It is mainly used for the second-line or third-line treatment of locally advanced or metastatic non-small cell lung cancer and for the treatment of pancreatic cancer. 2. HER-1/EGFR tyrosine kinase inhibitors. |
| Chemical Properties | Off-White Solid |
| Usage | Selective epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor. Antineoplastic |
| Usage | Erlotinib HCl is an HER1/EGFR inhibitor with IC50 of 2 nM. |
| Usage | Erlotinib HCl (OSI-744) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Phase 3. |
You Might Also Like
Related Searches
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View